Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Multiple Doses of GLPG2222 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation
Brief Summary: This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate 4 different doses of GLPG2222 administered for 4 weeks to adult subjects with a confirmed diagnosis of CF and homozygous for the F508del Cystic Fibrosis Transmembrane conductance Regulator (CFTR) mutation.


Options:
A: Arm Label: TEZ/IVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TEZ/IVA, Drug: IVA | Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA, TEZ/IVA
B: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren
C: Arm Label: 10 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: 50 mg (single dose); Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: 250 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: 250 mg (Fed); Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: 500 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Placebo-Day 1 only; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo-Day 1 only | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): 10 mg, 250 mg, 50 mg, 500 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): 250 mg (Fed), 50 mg (single dose) | Intervention Type: DRUG; Name: Placebo-Day 1 only; Assigned to Arm(s): Placebo-Day 1 only
D: Arm Label: Cohort A: GLPG2222 50 mg once daily (QD); Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 50 mg, Drug: Placebo | Arm Label: Cohort A: GLPG2222 100 mg QD; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 100 mg, Drug: Placebo | Arm Label: Cohort B: GLPG2222 200 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GLPG2222 200 mg | Arm Label: Cohort B: GLPG2222 400 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GLPG2222 400 mg | Arm Label: Cohort A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort B Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GLPG2222 50 mg; Assigned to Arm(s): Cohort A: GLPG2222 50 mg once daily (QD) | Intervention Type: DRUG; Name: GLPG2222 100 mg; Assigned to Arm(s): Cohort A: GLPG2222 100 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort A Placebo, Cohort A: GLPG2222 100 mg QD, Cohort A: GLPG2222 50 mg once daily (QD), Cohort B Placebo, Cohort B: GLPG2222 200 mg QD, Cohort B: GLPG2222 400 mg QD | Intervention Type: DRUG; Name: GLPG2222 200 mg; Assigned to Arm(s): Cohort B: GLPG2222 200 mg QD | Intervention Type: DRUG; Name: GLPG2222 400 mg; Assigned to Arm(s): Cohort B: GLPG2222 400 mg QD

Answer: D